AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

ClinicalTrials.gov ID: NCT01129193

Public ClinicalTrials.gov record NCT01129193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma

Study identification

NCT ID: NCT01129193
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Amir Mortazavi; Other
Enrollment: 44 participants

Conditions and interventions

Conditions

Interventions

AR-42 Drug
Fatigue Inventory Other
Pharmacodynamic Studies Other
Pharmacogenomic studies Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 3, 2010
Primary completion: Jan 6, 2017
Completion: Jan 6, 2017
Last update posted: Jun 3, 2018

2010 – 2017

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
The Ohio State University James Cancer Hospital	Columbus	Ohio	43210	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01129193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 3, 2018 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01129193 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →